Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
about
Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patientsAdjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk PatientsPhase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term resultsA phase II trial of dose-dense (biweekly) paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer.Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials.Organizing medical oncology care at a regional level and its subsequent impact on the quality of early breast cancer management: a before-after studyDose-Dense Chemotherapy: Principles, Clinical Results and Future Perspectives.G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonistConcurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial.Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer.Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts.Cancer and fertility preservation: fertility preservation in breast cancer patients.Fertility counseling of young breast cancer patients.Treatment of breast cancer in young women: do we need more aggressive therapies?Molecular Pathways: Targeting Cancer Stem Cells Awakened by Chemotherapy to Abrogate Tumor Repopulation.Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer.Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic reviewFeasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study.Dose-dense chemotherapy for breast cancer: what does the future hold?Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009).Medical approaches to preservation of fertility in female cancer patients.Dose-dense chemotherapy for breast cancer.Translating mathematical modeling of tumor growth patterns into novel therapeutic approaches for breast cancer.Chemotherapy regimens in early breast cancer: major controversies and future outlook.The development of dose-dense adjuvant chemotherapy.Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials.An overview of pregnancy and fertility issues in breast cancer patients.Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.News on the medical treatment of young women with early-stage HER2-negative breast cancer.Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.Re: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer.Treatment modifications of antineoplastic drugs in an oncology day-care unit.Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials.Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III TrialEvaluation of menopausal status among breast cancer patients with chemotherapy-induced amenorrhea
P2860
Q24198118-3E8BAFE0-7DD0-4852-8B7C-C62A365F2E58Q26751253-B41DE44C-AEFB-44B6-BA8A-2979EA9132F0Q33397922-10B36B9C-C23B-4D91-843D-A61950FA551AQ33430463-E676BD66-606C-4299-9206-BE91BAB60682Q33753705-7FBE15E5-AF57-493F-B24A-D02B12AD0B06Q33785011-75AB3196-4153-49BD-B1FC-087F84BE73E9Q34000716-22008F0C-E1CF-494E-9664-58C63CF40FF9Q34284284-F1956505-7547-45F6-846C-A7ADC8D56DAAQ35230245-6CF9A16B-3E37-4D0E-B4A1-1A20559AD796Q35460114-0953EB0B-C819-4DAE-A1C3-D0CD20EA2856Q35808451-BA44A965-6AC3-4DD3-A528-9BE17C404A12Q35842970-8694C8EB-5537-4262-9123-C7525832E20BQ36379148-24A34BC5-304B-434A-91B2-5C79A20FFA7EQ36678693-DFF2062B-BFD2-4C94-9E22-A6DE4BAAD6B9Q36963384-1FAE0854-D421-4B22-8875-E75E295546CDQ36963389-D9A6DE5E-E78B-4247-BCF5-C390EEFD3BE4Q37025965-FE02185C-7C76-4E3D-8CD8-DF9297597C5CQ37049920-7A4A87BE-393A-459C-ABBE-D9082C3BCA39Q37081127-74011110-8EB2-4BFC-9998-CE089C11B73CQ37213101-009DC0D1-49F7-4370-911A-7E41251468C9Q37309845-45FC1FA0-29EE-482A-A55A-FA8878FFFEBEQ37724850-A72B4BFB-C9ED-4A21-B846-9C154153D453Q37763100-078BB445-72BB-4467-BFBE-818D3C4B8746Q37827010-378A7178-C7B5-4639-8DC5-EF00CEA1F911Q37831349-3C0D6961-38E1-47BF-BA6F-A8399DC75FA3Q38009885-07D0E37B-05B8-4F15-9E85-2E2F850BEFC7Q38046516-E837450D-C406-40B5-8036-89E7AFBCEB7BQ38081243-BD0B1BBC-1706-431C-924B-6E8C977B9BEEQ38296287-6A328ECB-F909-4B4F-91E4-51BF13D94795Q38445535-651D4E00-EC8E-4C3C-9D28-663A3573E877Q38626663-6DE732C2-91EA-4B19-B418-6E40178B85B2Q38682028-1B2CEE21-2C91-4741-9225-797EEBF5F9A4Q38870541-64B0FFB8-B8A3-4017-849C-55AB27C5A506Q39375196-06DAE8BA-B2A0-46D5-9BEB-B746C99DBC0FQ44872215-016A01CB-C772-418B-83F8-0DF7E827C0D1Q47391721-B5935B5A-A90D-4DD8-B577-A740A119AD9DQ48594210-BEDC1D7E-AEE8-43C0-99ED-339A3C45D555Q55711832-C834E3F2-B6C1-4343-B18E-D389ED7B05DFQ57904482-C881FFBC-A1A5-46BF-B1DE-834A41974B80Q58804564-2AC6C0FC-AA0C-4DAB-A727-AD93D9E3884A
P2860
Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Dose-dense adjuvant chemothera ...... sults from a randomized trial.
@ast
Dose-dense adjuvant chemothera ...... sults from a randomized trial.
@en
type
label
Dose-dense adjuvant chemothera ...... sults from a randomized trial.
@ast
Dose-dense adjuvant chemothera ...... sults from a randomized trial.
@en
prefLabel
Dose-dense adjuvant chemothera ...... sults from a randomized trial.
@ast
Dose-dense adjuvant chemothera ...... sults from a randomized trial.
@en
P2093
P2860
P50
P356
P1476
Dose-dense adjuvant chemothera ...... sults from a randomized trial.
@en
P2093
Antonio Contu
Cinzia Caroti
Editta Baldini
Enrico Aitini
Franco Testore
Fulvio Brema
Giovanna Cavazzini
Giuseppe Canavese
Marco Venturini
Mario Roberto Sertoli
P2860
P304
P356
10.1093/JNCI/DJI398
P407
P577
2005-12-01T00:00:00Z